Last updated: 2026-09-07 00:46:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
4D Molecular Therapeutics, Inc. (FDMT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $14,96, with a market capitalization of $825,35M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6,09 to $16,93. This page covers its latest market performance, valuation, price trends and company information.
$825,35M | |
$14,50 | |
$55,11 | |
$2,24 | |
$14,70 | |
331,43K | |
-- | |
-- | |
$16,93 | |
$6,09 | |
-- | |
-- |
4D Molecular Therapeutics, Inc. (FDMT) last closed at $14,70 as of 2026-09-04 23:45:00, unchanged from the previous close of $14,70.
During the latest regular trading session, FDMT traded between $2,24 and $55,11, with a volume of 331,43K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, 4D Molecular Therapeutics, Inc. (FDMT) moved from $14,49 to $14,96, representing a gain of 3,24% ($0,47).
The stock traded between $14,30 and $15,01 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 881,53 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 81,8%
FDMT is currently trading at $14,96, placing it 81,8% of the way from its 52-week low of $6,09 to its 52-week high of $16,93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 196 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of 4D Molecular Therapeutics, Inc. (FDMT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.